Nov 8, 2024
The British pharmaceutical giant falsified patient test results to secure insurance coverage for its cancer drug in an effort to boost sales, but the alleged misconduct ended up benefiting some patients.
Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based...
Nov 1, 2024
Exploring the drive for quick returns among China’s state investors and how it contrasts with the country’s push for long-term investment in high-tech.
Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story:
Oct 25, 2024
Breaking down the country’s third-quarter GDP growth and what comes next.
Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story:
China’s Third-Quarter GDP Rises 4.6%, Beating Expectations
Subscribe now to unlock all coverage...
Oct 16, 2024
The impact of Beijing’s two-pronged approach on the country’s economic fundamentals remains to be seen.
Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on two Caixin stories:
Oct 10, 2024
Ex-Taoist monk Sui Guangyi claimed to make investments by aligning heaven, earth and humanity. His company’s 2018 gala even featured former national leaders like Nicolas Sarkozy and Kevin Rudd. But now, investors are left waiting to get their money back.
Note: The conversation segment of this episode was...